[Pubmed] Causal effects of Epstein-Barr virus antibodies on autoimmune neuroinflammatory diseases: A generalised summary

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6503
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Android Chrome

[Pubmed] Causal effects of Epstein-Barr virus antibodies on autoimmune neuroinflammatory diseases: A generalised summary

Message par RSS-Bot »


Medicine (Baltimore). 2026 Apr 10;105(15):e48264. doi: 10.1097/MD.0000000000048264.

ABSTRACT

Observational studies associate Epstein-Barr virus (EBV) with multiple sclerosis (MS), but causality across autoimmune neuroinflammatory diseases (ANDs) remains uncertain. This study aimed to assess the causal effects of 5 EBV antibodies on ANDs using Mendelian randomization (MR). Bidirectional, two-sample MR was performed using generalized summary-data-based MR (GSMR). Genetic instruments for EBV antibodies (anti-EBNA-1, VCA p18, ZEBRA, EA-D, IgG) were sourced from UK Biobank (UKB). Outcome data for ANDs (multiple sclerosis [MS], neuromyelitis optica [NMO], myasthenia gravis [MG], Guillain-Barré syndrome [GBS], and chronic inflammatory demyelinating polyneuropathy [CIDP]) were from FinnGen (discovery), UKB, and International Multiple Sclerosis Genetics Consortium (replication). Applying an evidence-tiered interpretation, we found a high-confidence, protective causal effect of increased ZEBRA antibody levels on MS risk (odds ratio [OR] = 0.705, P = 2.967 × 10-6), which was robust to multiple testing nominally supported in an independent cohort (IMSGC). In contrast, the association between EBNA-1 antibodies and increased MS risk (OR = 1.284, P = 2.450 × 10-4) was graded as suggestive as it showed nominal support only in one of 2 validation cohorts (UKB) and was substantially attenuated after excluding HLA-region single nucleotide polymorphisms, indicating shared genetic architecture rather than direct causation. Steiger directionality tests confirmed the primary causal direction was from antibodies to MS. Results for NMO, MG, GBS, and CIDP were inconclusive due to limited statistical power, and thus no definitive conclusions can be drawn regarding EBV antibodies and these diseases. This study provides high-confidence genetic evidence for a protective role of ZEBRA antibodies in MS, which was robust to multiple testing and nominally supported in an independent cohort [International MS Genetics Consortium (IMSGC)], and suggestive evidence for an HLA-mediated link between EBV-encoded nuclear antigen-1 (EBNA-1) and MS which showed nominal support only in one of 2 validation cohorts. The role of EBV in other ANDs warrants investigation in larger, well-powered cohorts.

PMID:41961712 | DOI:10.1097/MD.0000000000048264


Source: https://pubmed.ncbi.nlm.nih.gov/4196171 ... t6+133c1fe
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »